Closed · W81XWH-14-DMRDP-MID-ARA · CFDA 12.420 · Discretionary
DOD Military Infectious Diseases Applied Research Award
Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- October 17, 2013
- Close date
- 5
- Expected awards
The verdict
DOD Military Infectious Diseases Applied Research Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 5 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.
- Varies
- award range
- Closed
- application status
- 5
- expected awards
- 12.420
- CFDA program
Archived opportunity record
DOD Military Infectious Diseases Applied Rese… is closed (last close October 17, 2013). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed October 17, 2013
Est. Total Funding
$11,100,000
Expected Awards
5
Instrument
Grant
Description
All applications MUST specifically address at least one of the MID-ARA Focus Areas related to combat-related or trauma-induced wound infections. Research projects incorporating high-throughput drug screening and/or in silico modeling, as well as applications focused on areas other than those listed below should NOT be submitted. The MID-ARA Focus Areas are:• Development of new methods for rapid multi-pathogen/multi-phenotype detection of multidrug-resistant organisms (MDROs), nosocomial pathogens, and/or rapid multi-pathogen/multi-phenotype characterization of antimicrobial resistance patterns.• Development of assays for host immune response biomarkers for diagnosis or prognosis (with associated outcomes) of infection to inform clinical wound management decisions (e.g., optimal wound closure time, optimal duration of antibiotics for osteomyelitis).• Development and preclinical testing of novel chemotypes (chemical classes/materials), biologics as potential therapeutics or prophylactics for wound infection, and/or biofilm formation, maintenance, or propagation. Innovative treatment approaches (e.g., chelators, antibody, phage, antimicrobial peptides, quorum-sensing inhibitors, and host immunoaugmentation, etc.) are encouraged.NOTES FOR ALL FOCUS AREAS:• Preference will be given to approaches that address infections with one or more multi-drug resistant organisms (MDROs), particularly, Acinetobacter baumannii, Pseudomonas aeruginosa, extended-spectrum beta-lactamase producing Enterobacteriaceae (including Escherichia coli and Klebsiella pneumoniae), and methicillin-resistant Staphylococcus aureus (MRSA), and/or invasive fungal (mold) pathogens.• Preference will be given to studies leading toward topical treatments for prevention and management of wound infection. Overview: The FY14 DMRDP MID-ARA seeks applied research applications focused on the reduction of combat-related or trauma-induced wound infection morbidity and mortality. These awards are expected to yield potential health products, approaches, or technologies positioned for human testing. The intent of the FY14 DMRDP MID-ARA is to support:• Hypothesis-testing and/or proof-of-concept studies in in vitro and/or in vivo models;• Refinement of concepts and ideas into potential solutions with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new products;• Evaluation, maturation, and/or down-selection of potential product candidates (drugs, biologic/vaccine constructs, or devices/systems) in vitro and/or in vivo and;• Completion of preclinical safety and/or toxicity studies sufficient to support Investigational New Drug/Investigational Device Exemption (IND/IDE) applications.Awards may support studies with human subjects but may not be used to support clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction.Awards may not be used to support fundamental basic research. Basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind.Presentation of preliminary data is required. Investigators must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale.Partnering Principal Investigator (PI) Option: The FY14 DMRDP MID-ARA mechanism supports applications that include meaningful and productive collaborations. The Partnering PIOption under this mechanism is structured to accommodate up to three PIs who will each receive a separate award. One partner is identified as the Initiating PI and the other partner(s) as the Partnering PI(s). All investigators should collaborate in the development and submission of the proposed research project. It should be clear that each investigator has a significant level of intellectual input and brings complementary strengths to the project. Multidisciplinary and multi-organizational projects are allowed. If multi-organizational, participating organizations must be willing to resolve potential intellectual and material property issues and remove any barriers that might interfere with successful completion of the research.
Catch-all / unrestricted eligibility mark · W81XWH-14-DMRDP-MID-ARA
Grants.gov marks DOD Military Infectious Diseases Applied Rese… with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).
- Code 99
- Unrestricted / see official listing
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
CDMRP Help Desk 301-682-5507
More from Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
DoW Neurofibromatosis Investigator-Initiated Research Award
DoW Neurofibromatosis Research Academy – Scholar Award
DoW Neurofibromatosis Exploration-Hypothesis Development Award
DOW Combat Readiness – Medical Research Program Translational Research Award
What to do next
DOD Military Infectious Diseases Applied Rese… is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- Compare award ranges across federal categories before you pick a single CFDA. All categories
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |